Washington, D.C., Sept. 06, 2017 -- The Cancer Support Community (CSC), an international nonprofit, today announced the launch of Immunotherapy & Me, an innovative program to support the unique needs of patients receiving immunotherapy treatment, and the clinical staff who care for them. The program aims to identify and implement patient-centered practice solutions across the continuum of immunotherapy care.
|
|||
“The Cancer Support Community sees that immunotherapy is greatly impacting how we treat cancer, with marked advances in the treatment of lung, melanoma, genitourinary, hematologic, head and neck cancers, and more,” said Kim Thiboldeaux, CEO, Cancer Support Community. “This is why we are so excited to work with our pilot partners to improve the experience of patients receiving immunotherapy and to help establish clinical practice tools to advance quality care.”
Immunotherapy uses the body’s own immune system to fight cancer. Given the unique way immunotherapy engages the immune system, recognition and management of side effects can be challenging. Patients and health care teams share the responsibility of promptly reporting treatment-related symptoms, however, patients often require additional education, support, and resources to become active partners in their care.
Immunotherapy & Me addresses this by empowering patients to promptly report treatment-related side effects and by providing staff the resources to streamline patient education around symptom management. Immunotherapy & Me will be piloted at nine oncology practice sites for twelve months, including the collection and reporting of patient outcomes. A core component of this initiative will be assessing patient levels of distress using CSC’s CancerSupportSource® to document program impact on the overall patient experience. Immunotherapy & Me offers patients and staff three categories of activation tools: a web-based app to monitor treatment-related side effects; educational materials that are both immunotherapy-specific and general cancer information; and an expansion of CSC’s existing Cancer Support Helpline to include registered nurses to assist patients and families with concerns related to their clinical care.
“The tools and framework the Cancer Support Community provides through the Immunotherapy & Me pilot are invaluable to our team of physicians, nurses, social workers, navigators, and researchers,” said Dr. Lee Schwartzberg, MD, FACP, medical oncologist and Executive Director of the West Cancer Center based in Memphis, Tennessee. “By engaging a wide-variety of touchpoints—on-site, online, and, over the phone—we maximize patient engagement, can better monitor patient progress, and hope to improve patient outcomes.”
CSC is partnering with nine highly regarded oncology practices for this pilot. These practices allow CSC to bring interventions to immunotherapy patients at the point-of-care while reaching geographically and demographically diverse patient populations. These pilot sites are:
Catholic Health Initiatives
- Harrison Medical Center – Bremerton, Washington
- Harrison Medical Center – Poulsbo, Washington
Centura Health
- Littleton Adventist Hospital – Littleton, Colorado
- Parker Adventist Hospital – Parker, Colorado
- Porter Adventist Hospital – Denver, Colorado
OHC (Formerly Oncology Hematology Care, Inc.)
- OHC West Office – Cincinnati, Ohio
Roswell Park Cancer Institute – Buffalo, New York
West Cancer Center
- West Cancer Center: Corinth – Corinth, Mississippi
- West Cancer Center: Wolf River – Memphis, Tennessee
The Immunotherapy & Me program is made possible through the generous financial support of Bristol-Myers Squibb.
###
About the Cancer Support Community
As the largest professionally led nonprofit network of cancer support worldwide, the Cancer Support Community (CSC), including its Gilda’s Club affiliates, is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action, and sustained by community. CSC achieves its mission through three areas: direct service delivery, research, and advocacy. The organization includes an international network of Affiliates that offer the highest quality social and emotional support for people impacted by cancer, as well as a community of support available online and over the phone. The Research and Training Institute conducts cutting-edge psychosocial, behavioral, and survivorship research. CSC furthers its focus on patient advocacy through its Cancer Policy Institute, informing public policy in Washington, D.C. and across the nation. For more information, please call the toll-free Cancer Support Helpline at 888-793-9355, or visit www.CancerSupportCommunity.org. So that no one faces cancer alone.®
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/e0bda697-1151-4c20-9546-b24e062a4a9a
Henry Duong Cancer Support Community 6262839563 [email protected]


Italy Fines Apple €98.6 Million Over App Store Dominance
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 



